Universal Technical Institute operates as a leading workforce education provider through two main divisions: UTI for transportation, skilled trades, and energy programs, and Concorde Career Colleges for allied health, dental, and nursing. The fiscal fourth quarter, ended September 30, 2026, marks the close of the second year under the company's "North Star" growth strategy focused on new campus openings, program expansion, and diversification into healthcare. This report draws attention because it shows whether enrollment momentum is translating into scalable profitability or if deliberate expansion spending is affecting near-term earnings. With several new campuses ramping up and significant investments planned for fiscal 2027, the quarter serves as an important checkpoint on the longer-term growth path. I also checked this using Tickeron's AI Screener to see how the stock compares to others in the industry.
In the fiscal 2026 fourth quarter, Universal Technical Institute posted revenue of $235.9 million, a 6.0% increase from $222.4 million a year earlier and roughly in line with analyst estimates. Adjusted EPS came in at $0.32, missing the consensus forecast of $0.52 by $0.20 as growth investments and higher operating costs pressured results. Net income attributable to common shareholders was $18.0 million.
For the full fiscal year, revenue grew 7.4% to $897.0 million. Adjusted EBITDA declined 19.3% to $102.0 million, reflecting about $34.6 million in strategic growth expenses tied to new campuses and program launches. Operating metrics stayed solid: new student starts increased 7.0% to 31,873, while average full-time active students rose 6.6% to 26,251.
Management issued fiscal 2027 guidance for revenue of $925 million to $945 million, above the analyst consensus of roughly $896 million. However, EPS guidance of $0.00 to $0.09 landed well below expectations and below the fiscal 2026 full-year result of $0.60, as the company plans roughly $35 million in growth investments to support four new campus openings and ongoing program expansion.
Universal Technical Institute shares fell sharply in after-hours trading following the release, with early reports indicating a decline of roughly 10% as investors reacted to the weaker-than-expected EPS guidance for fiscal 2027. While the company's revenue outlook came in above consensus, the sharp projected drop in per-share earnings—reflecting continued heavy investment in new campuses and programs—appeared to dominate the market's initial interpretation.
The reaction highlights a tension in the investment narrative: strong enrollment and demand fundamentals are being offset, at least in the near term, by the cost of an ambitious expansion program. Management has framed these outlays as disciplined, high-return investments that should improve margins as new locations scale, but the market's immediate response suggests investors are weighing the timeline of that payoff carefully. From what I see, this dynamic is worth monitoring closely.
Looking ahead, investors will focus on how quickly newly opened campuses, including UTI Atlanta and UTI San Antonio, ramp toward their projected mature enrollment levels. These locations are expected to serve roughly 1,500 and 800 students annually, respectively, and their fill rates will be an important signal of whether growth investments are converting into sustainable revenue.
Margin recovery is another key theme. Management has indicated that the bulk of fiscal 2027's growth spending will compress reported profitability before easing in subsequent years. Tracking adjusted EBITDA and the pace of new campus openings—four are planned for fiscal 2027—will help investors gauge whether the company is on schedule with its longer-term targets.
Finally, regulatory and funding dynamics remain relevant. Delays in federal student-aid disbursements and changes to verification processes have previously affected cash flow timing, so monitoring receivables and operating cash flow will matter. Demand fundamentals for skilled trades and healthcare workers remain structurally strong, but execution on the expansion pipeline will ultimately determine whether Universal Technical Institute can translate enrollment growth into higher earnings. I’m watching this closely as the story unfolds.
In my analysis of UTI and similar names, I find Tickeron's AI Screener particularly useful for quickly filtering stocks by industry, technical indicators, and performance metrics. It helps surface comparable opportunities and sector trends in less time than manual reviews, supporting a more data-driven approach to research without replacing core fundamental work.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where UTI declined for three days, in 196 of 262 cases, the price declined further within the following month. The odds of a continued downward trend are 75%.
The 10-day RSI Indicator for UTI moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 28 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 68 cases where UTI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 69%.
The Momentum Indicator moved above the 0 level on November 16, 2026. You may want to consider a long position or call options on UTI as a result. In 74 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for UTI just turned positive on November 10, 2026. Looking at past instances where UTI's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
UTI moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for UTI crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +16.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where UTI advanced for three days, in 259 of 330 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
UTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 185 of 250 cases where UTI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. UTI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock better than average.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: UTI's P/B Ratio (3.189) is slightly higher than the industry average of (1.158). UTI has a moderately high P/E Ratio (32.145) as compared to the industry average of (8.484). Projected Growth (PEG Ratio) (1.642) is also within normal values, averaging (1.327). Dividend Yield (0.004) settles around the average of (4.151) among similar stocks. P/S Ratio (1.320) is also within normal values, averaging (27.566).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of technical education
Industry OtherConsumerSpecialties